Katarzyna Karłowicz, Konrad Lewandowski, Edyta Tulewicz-Marti, Katarzyna Maciejewska, Adam Tworek, Beata Stępień-Wrochna, Martyna Głuszek-Osuch, Michał Łodyga, Grażyna Rydzewska
{"title":"炎症性肠病 (IBD) 患者接种 SARS-CoV-2 疫苗--IBD 治疗是否会对 SARS-CoV-2 抗体产生负面影响？一项单中心前瞻性研究。","authors":"Katarzyna Karłowicz, Konrad Lewandowski, Edyta Tulewicz-Marti, Katarzyna Maciejewska, Adam Tworek, Beata Stępień-Wrochna, Martyna Głuszek-Osuch, Michał Łodyga, Grażyna Rydzewska","doi":"10.5114/pg.2023.130126","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Inflammatory bowel disease (IBD) patients use a wide variety of immunosuppressive drugs, including biologics, but their effect on SARS-CoV-2 vaccine antibody levels remains a mystery.</p><p><strong>Aim: </strong>We analysed whether the drugs used in the treatment of IBD patients could affect the concentration of SARS-CoV-2 antibodies.</p><p><strong>Material and methods: </strong>This is a prospective, single-centre evaluation of the persistence of SARS-CoV-2 antibodies after vaccination at various time points: every 2 months throughout the 6<sup>th</sup> month after the first dose.</p><p><strong>Results: </strong>We included a total of 346 vaccinated IBD patients in the study. A negative correlation between antibody level and time from full vaccination was confirmed for the following types of therapy: infliximab (rho = -0.32, <i>p</i> < 0.001), adalimumab (rho = -0.35, <i>p</i> = 0.025), and vedolizumab (rho = -0.50, <i>p</i> < 0.001). In the case of other, long-term drug administration, a negative correlation between antibody level and time from full vaccination was confirmed for mesalazine (rho = -0.35, <i>p</i> < 0.001), budesonide (rho = -0.58, <i>p</i> = 0.004), systemic glucocorticoids (rho = -0.58, <i>p</i> < 0.001), and azathioprine (rho = -0.44, <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Due to the immunosuppressive and biological treatment, IBD patients are exposed to a shorter persistence of SARS-CoV-2 antibodies and require booster doses. The role of gastroenterologists in educating patients about the need to continue SARS-CoV-2 vaccination remains crucial.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200064/pdf/","citationCount":"0","resultStr":"{\"title\":\"SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients - does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study.\",\"authors\":\"Katarzyna Karłowicz, Konrad Lewandowski, Edyta Tulewicz-Marti, Katarzyna Maciejewska, Adam Tworek, Beata Stępień-Wrochna, Martyna Głuszek-Osuch, Michał Łodyga, Grażyna Rydzewska\",\"doi\":\"10.5114/pg.2023.130126\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Inflammatory bowel disease (IBD) patients use a wide variety of immunosuppressive drugs, including biologics, but their effect on SARS-CoV-2 vaccine antibody levels remains a mystery.</p><p><strong>Aim: </strong>We analysed whether the drugs used in the treatment of IBD patients could affect the concentration of SARS-CoV-2 antibodies.</p><p><strong>Material and methods: </strong>This is a prospective, single-centre evaluation of the persistence of SARS-CoV-2 antibodies after vaccination at various time points: every 2 months throughout the 6<sup>th</sup> month after the first dose.</p><p><strong>Results: </strong>We included a total of 346 vaccinated IBD patients in the study. A negative correlation between antibody level and time from full vaccination was confirmed for the following types of therapy: infliximab (rho = -0.32, <i>p</i> < 0.001), adalimumab (rho = -0.35, <i>p</i> = 0.025), and vedolizumab (rho = -0.50, <i>p</i> < 0.001). In the case of other, long-term drug administration, a negative correlation between antibody level and time from full vaccination was confirmed for mesalazine (rho = -0.35, <i>p</i> < 0.001), budesonide (rho = -0.58, <i>p</i> = 0.004), systemic glucocorticoids (rho = -0.58, <i>p</i> < 0.001), and azathioprine (rho = -0.44, <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Due to the immunosuppressive and biological treatment, IBD patients are exposed to a shorter persistence of SARS-CoV-2 antibodies and require booster doses. The role of gastroenterologists in educating patients about the need to continue SARS-CoV-2 vaccination remains crucial.</p>\",\"PeriodicalId\":20719,\"journal\":{\"name\":\"Przegla̜d Gastroenterologiczny\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200064/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Przegla̜d Gastroenterologiczny\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/pg.2023.130126\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/7/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Przegla̜d Gastroenterologiczny","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pg.2023.130126","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients - does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study.
Introduction: Inflammatory bowel disease (IBD) patients use a wide variety of immunosuppressive drugs, including biologics, but their effect on SARS-CoV-2 vaccine antibody levels remains a mystery.
Aim: We analysed whether the drugs used in the treatment of IBD patients could affect the concentration of SARS-CoV-2 antibodies.
Material and methods: This is a prospective, single-centre evaluation of the persistence of SARS-CoV-2 antibodies after vaccination at various time points: every 2 months throughout the 6th month after the first dose.
Results: We included a total of 346 vaccinated IBD patients in the study. A negative correlation between antibody level and time from full vaccination was confirmed for the following types of therapy: infliximab (rho = -0.32, p < 0.001), adalimumab (rho = -0.35, p = 0.025), and vedolizumab (rho = -0.50, p < 0.001). In the case of other, long-term drug administration, a negative correlation between antibody level and time from full vaccination was confirmed for mesalazine (rho = -0.35, p < 0.001), budesonide (rho = -0.58, p = 0.004), systemic glucocorticoids (rho = -0.58, p < 0.001), and azathioprine (rho = -0.44, p < 0.001).
Conclusions: Due to the immunosuppressive and biological treatment, IBD patients are exposed to a shorter persistence of SARS-CoV-2 antibodies and require booster doses. The role of gastroenterologists in educating patients about the need to continue SARS-CoV-2 vaccination remains crucial.
期刊介绍：
Gastroenterology Review is a journal published each 2 months, aimed at gastroenterologists and general practitioners. Published under the patronage of Consultant in Gastroenterology and Polish Pancreatic Club.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
